Cisplatin benefit is predicted by immunohistochemical analysis of DNA repair proteins in squamous cell carcinoma but not adenocarcinoma: theranostic modeling by NSCLC constituent histological subclasses-Reference-Cited by-同舟云学术

Cisplatin benefit is predicted by immunohistochemical analysis of DNA repair proteins in squamous cell carcinoma but not adenocarcinoma: theranostic modeling by NSCLC constituent histological subclasses

Published:2012-09 Issue:9 Volume:23 Page:2245-2252
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Pierceall W.E.,Olaussen K.A.,Rousseau V.,Brambilla E.,Sprott K.M.,Andre F.,Pignon J.-P.,Le Chevalier T.,Pirker R.,Jiang C.,Filipits M.,Chen Y.,Kutok J.L.,Weaver D.T.,Ward B.E.,Soria J.-C.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/23/9/2245/13787805/mdr624.pdf

Reference34 articles.

1. APE1 overexpression is associated with cisplatin resistance in non-small cell lung cancer and targeted inhibition of APE1 enhances the activity of cisplatin in A549 cells;Wang;Lung Cancer,2009

2. The prognostic significance of ERCC1, BRCA1, XRCC1, and betaIII-tubulin expression in patients with non-small cell lung cancer treated by platinum- and taxane-based neoadjuvant chemotherapy and surgical resection;Kang;Lung Cancer,2009

3. Mismatch repair system (MMR) status correlates with response and survival in non-small cell lung cancer (NSCLC) patients;Scartozzi;Lung Cancer,2006

4. Polymerase eta mRNA expression predicts survival of non-small cell lung cancer patients treated with platinum-based chemotherapy;Ceppi;Clin Cancer Res,2009

5. DNA repair by ERCC1 in non–small cell lung cancer and cisplatin-based adjuvant chemotherapy;Olaussen;New Engl J Med,2006

Cited by 59 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Synergistic effects of olaparib combined with ERCC1 on the sensitivity of cisplatin in non‑small cell lung cancer;Oncology Letters;2021-03-10

2. Adjuvant platinum-based chemotherapy in non-small cell lung cancer: The role of relative dose-intensity and treatment delay;Cancer Treatment and Research Communications;2021

3. Identification of PDL1-Related Biomarkers to Select Lung Adenocarcinoma Patients for PD1/PDL1 Inhibitors;Disease Markers;2020-06-10

4. The value of CEP55 gene as a diagnostic biomarker and independent prognostic factor in LUAD and LUSC;PLOS ONE;2020-05-21

5. The Effect of NNK, A Tobacco Smoke Carcinogen, on the miRNA and Mismatch DNA Repair Expression Profiles in Lung and Head and Neck Squamous Cancer Cells;Cells;2020-04-21